Search Results
Your search for c matches 3834 pages
Showing 101 - 150The Future of Cell Therapy: Optimizing the CAR to the Disease in B-Cell Malignancies
Over the past 20 years, increased understanding of the biological mechanism of disease has led to improved treatment options for all malignancies. Within each disease subtype, we have molecularly characterized tumors and developed specific treatment algorithms to optimize patient outcomes. Among...
Nivolumab or Brentuximab Vedotin With AVD in Older Patients With Advanced Classical Hodgkin Lymphoma
In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes of nivolumab plus AVD (doxorubicin, vinblastine, dacarbazine; N-AVD) vs brentuximab vedotin plus AVD (BV-AVD) in patients with advanced-stage...
Can Planned C-Sections Increase the Risk of Childhood ALL?
Children born by planned cesarean section (C-section) may have an increased risk of developing acute lymphoblastic leukemia (ALL) later in life, according to a recent study published by Kampitsi et al in the International Journal of Cancer. Alhough the researchers did find an association, they...
Early Toxicity With Moderately Hypofractionated vs Stereotactic Body Radiotherapy in Prostate Cancer
In an analysis from a phase III trial (PACE-C) reported in The Lancet Oncology, Tree et al compared early toxicity rates with intensity-modulated moderately hypofractionated radiotherapy (MHRT) vs stereotactic body radiotherapy (SBRT) in patients with intermediate- and high-risk prostate...
New Data Show Nearly 50% of All Cancer Deaths Worldwide Are Attributable to Modifiable Risk Factors
New reporting in The Cancer Atlas, Fourth Edition, showed that an estimated 50% of all cancer deaths worldwide are attributed to modifiable risk factors, including tobacco and alcohol use, infections, excess body weight, unhealthy diet, physical inactivity, ultraviolet radiation, environmental...
GPC3-Targeted ImmunoPET Helps Detect Earlier-Stage Hepatocellular Carcinoma
A novel immuno–positron-emission tomography (immunoPET) imaging agent targeting GPC3 demonstrated high sensitivity and specificity in detecting GPC3-positive hepatocellular carcinoma (HCC) tumors, including those under 1 cm, according to the results of a pilot clinical study presented at the...
William C. Wood, MD, FASCO, Renowned Surgeon, Esteemed Mentor, Global Academic Dean, Dies at 84
William C. “Bill” Wood, MD, FASCO, a leader and mentor in the field of breast cancer, died on August 18, 2024. He was 84. Dr. Wood was the J.B. Whitehead Professor and Chair of the Department of Surgery at Emory University School of Medicine from 1991 to 2009. He chaired the 1990 U.S. National...
Minnesota Society of Clinical Oncology Recognized for Advocacy at 2025 ASCO Annual Meeting
The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State Affiliates’ Reception at the 2025 ASCO Annual Meeting. Presented annually, the Jeffery C. Ward...
Chinese Herbal Medicine for Improving Adjuvant Chemotherapy Completion in Patients With Colon Cancer
Guest Editor’s Note: Although guidelines recommend adjuvant combination chemotherapy for patients with stage II and III colon cancer who are at high risk of disease recurrence, fewer than 50% complete treatment because of fear of adverse effects or symptom burden. The herbal formula Jianpi Bushen ...
HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies
Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...
ASCO Guideline Update Calls for Omission of SLNB in Select Patients With Early-Stage Breast Cancer
ASCO has released a clinical practice guideline update on the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer.1 The update includes recommendations based on findings from trials released after the published guideline in 2017, including data from nine randomized trials...
Early ESR1 Mutation Detection and Therapy Switch in Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer
Early detection of an ESR1 mutation, leading to a switch of endocrine therapy, led to an almost doubling in progression-free survival in the SERENA-6 trial, the global registrational study in patients with metastatic breast cancer for the investigational oral selective estrogen receptor degrader...
New Model Predicts Risk of Progression in Early-Stage Classical Hodgkin Lymphoma
The first individualized risk prediction model for adults with early-stage classical Hodgkin lymphoma (cHL) has been developed and validated. According to a report published in NEJM Evidence, the Early-Stage cHL International Prognostic Index (E-HIPI) model estimates 2-year progression-free...
How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival
A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....
Novel Tri-Specific Antibody Shows Efficacy and Safety in Refractory Myeloma
According to the initial findings of an ongoing first-in-human phase I trial, reported at the European Hematology Association (EHA) 2025 Congress, promising results have been shown for a novel off-the-shelf tri-specific antibody in the treatment of patients with multiple myeloma highly refractory...
Experimental Approach to Graft-vs-Host Disease Prophylaxis Offers Alternative to Standard Regimen
Prevention of graft-vs-host disease was far superior with a cyclophosphamide/cyclosporin-based regimen than with standard prophylaxis in patients receiving a matched-sibling donor stem cell transplant in a large Australian randomized trial, investigators reported at the European Hematology...
Elevated Cardiac Biomarkers Associated With Increased Cancer Risk
Higher baseline levels of certain cardiac biomarkers were associated with an increased risk of future incidence of cancer, according to findings from a study published in the Journal of the American College of Cardiology: Advances. Higher incidence rates for all cancers were associated with higher ...
Order of CRC Diagnosis May Influence Survival in Patients With Multiple Malignancies
The order of colorectal cancer diagnosis seems to have a significant impact on outcomes in patients with multiple primary malignancies, according to the results of a study of Surveillance, Epidemiology, and End Results (SEER) Program data. Findings from the study were published in the Journal of...
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared disease-free survival outcomes of adjuvant cemiplimab vs placebo in patients with high-risk cutaneous squamous cell carcinoma. Study Details In the trial, 415...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer
“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who...
Potential New Standard of Care Emerges in Multiple Myeloma
A new four-drug combination appears to be effective and safe in patients with newly diagnosed multiple myeloma, according to data from the ADVANCE clinical trial conducted by investigators at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. Presented ...
Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer
Greater intake of a proinflammatory dietary pattern may be linked to worse overall survival in patients with stage III colon cancer who have undergone curative-intent resection. Sara K. Char, MD, a clinical fellow at Dana-Farber Cancer Institute, Boston, presented the results of a prospective...
Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with...
Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, on CLL/SLL: First-Line Zanubrutinib Monotherapy in Patients With del(17p)
Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7011).
Nicholas C. Turner, MD, PhD, on INAVO120: Final Overall Survival Analysis
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents final overall survival data from the INAVO120 trial of inavolisib/placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer (Abstract 1003).
Bringing Evidence-Based Integrative Medicine Into Everyday Oncology Practice
Despite the significant rise over the past 50 years in the use of evidence-based integrative medicine in conjunction with conventional cancer treatments—up from just 20% in the 1970s to about 80% in 20171—training opportunities in the fundamentals of this emerging field within the specialty of...
In Case You Missed It: Additional Abstracts of Interest in Cancer Research
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
Inavolisib-Based Regimen in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
New findings from the phase III INAVO120 trial showed that adding inavolisib to palbociclib and fulvestrant may help extend survival and delay the time until treatment with chemotherapy in previously treated patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. The...
Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphomas of B cells and T cells. We now know DLBCL is still heterogenous and some subtypes might benefit...
Antimicrobial Resistance in Outpatients With Cancer
In a U.S. multicenter retrospective cohort study reported in The Lancet Oncology, Gupta et al evaluated whether antimicrobial resistance was more common in pathogenic bacterial isolates from outpatients with cancer than in outpatients without cancer. Study Details The study involved data from the...
FDA Approves Therapy for NSCLC With High c-Met Protein Overexpression
On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a c-Met–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, nonsquamous, non–small cell lung cancer (NSCLC) with high c-Met ...
NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...
Cohort Study Shows Benefits of Bilateral Salpingo-Oophorectomy Without Increased Health Risks
Patients with a history of breast cancer who are carriers of BRCA1 and BRCA2 pathogenic variants benefit from undergoing bilateral salpingo-oophorectomy, the results of a retrospective cohort study published in The Lancet Oncology showed. Women who had their ovaries and fallopian tubes removed...
In Case You Missed It: Additional Abstracts of Interest From AACR
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
ASH Studies Bolster Support for Menin Inhibitor in Acute Leukemia
The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement. Approval was...
2024 Annual Report to the Nation on the Status of Cancer Finds Mortality Rates Continue to Decline
Overall deaths from cancer over the past 2 decades have steadily declined in both men and women in the United States, according to the 2024 Annual Report to the Nation on the Status of Cancer, which was published by Recinda L. Sherman, MPH, PhD, ODS-C, of the North American Association of Central...
Symptoms Preceding Unplanned Acute Care in Patients With Cancer
In a single-institution cohort study reported in JAMA Network Open, Chang et al identified patterns of symptoms preceding unplanned acute care encounters for patients with cancer. Study Details The study involved data from all unplanned acute care encounters (emergency department visits and...
Radiotherapy for Prostate Cancer: 2- vs 8-Week Course
The phase III HYPO-RT-PC trial has shown that a 2-week course of radiotherapy for localized prostate cancer—also known as ultra-hypofractionated radiotherapy—may be just as safe and effective as the traditional 8-week schedule—even 10 years after treatment. The findings were presented at the 2025...
AACR 2025: Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D–Mutated NSCLC
The oral KRAS G12D inhibitor zoldonrasib could provide clinical benefit in patients with previously treated non–small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation, according to new findings presented by Arbour et al at the 2025 American Association for Cancer Research (AACR)...
ASCO Updates Guideline for Fertility Preservation in People With Cancer
ASCO has released an update to the guideline for fertility preservation in people with cancer. The update, recently published in the Journal of Clinical Oncology,1 provides recommendations regarding evaluation and counseling for fertility preservation; methods and timing of fertility preservation;...
Managing Dermatologic Reactions to Combination Therapy for Patients With EGFR-Mutated NSCLC
Nicolas Girard, MD, a thoracic oncologist at the Institut Curie, Paris, presented the results of an interim analysis of the open-label phase II COCOON study, at the European Lung Cancer Congress (ELCC) 2025.1 A readily available preventive regimen (the COCOON regimen) reduced moderate-to-severe...
Updated CAP Guideline Aims to Address Rising Rates of HPV-Associated Squamous Cell Carcinomas
The College of American Pathologists (CAP) updated its testing guideline to capture new research and emerging technologies to improve the diagnostic accuracy of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinomas, according to a guideline update published by Lewis et al in...
Combination Therapy for Newly Diagnosed, BRCA-Nonmutated, Advanced Epithelial Ovarian Cancer
The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inhibitor pembrolizumab and chemotherapy, followed by pembrolizumab plus maintenance with the PARP...
FDA Expands Indication for Lu-177 Vipivotide Tetraxetan in mCRPC
On March 28, the U.S. Food and Drug Administration (FDA) expanded the indication for lutetium Lu-177 vipivotide tetraxetan (Pluvicto) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen ...
Building and Sharing Dietary Evidence in Cancer Care
Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are often interested in exploring different dietary interventions throughout the cancer continuum. However, concrete...
Conundrums in Treating HER2-Positive Early Breast Cancer
Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Conference, Sara A. Hurvitz, MD, FACP, offered insight on common clinical scenarios. Dr. Hurvitz is...
Virtual Reality Therapy May Improve Chemotherapy-Associated Side Effects
A study conducted by Stansel et al, which was published in the journal Clinical Journal of Oncology Nursing, highlighted the potential of virtual reality therapy to reduce patient stress, pain, and negative affect during chemotherapy sessions. The findings also appeared to support its delivery and...
New Guideline Supports Transoral Robotic Surgery in the Multidisciplinary Management of Patients With Oropharyngeal Cancer
Transoral robotic surgery (TORS) can offer patients with oropharyngeal squamous cell carcinoma (OPSCC) improved survival while minimizing or avoiding late toxicities associated with the standard of care of radiation with cisplatin chemotherapy, according to a recent ASCO guideline.1 “We show in a...
New ASCO Guideline Addresses Germline and Somatic Genomic Testing in Metastatic Prostate Cancer
Prostate carcinoma is the most common type of cancer among men in the United States, accounting for more than 299,000 estimated new cases and approximately 35,000 new deaths in 2024.1 A new ASCO guideline based on findings from a systematic review indicates that in metastatic cases of prostate...
